There are 2934 resources available
1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study
Presenter: Luis Garcia Rodriguez
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Poster Discussion – Gastrointestinal tumours, non-colorectal - Invited Discussant 673PD and 674PD
Presenter: Hanneke van Laarhoven
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
Poster Discussion – Gastrointestinal tumours, non-colorectal - Invited Discussant LBA45, LBA46, 675PD and 676PD
Presenter: Florian Lordick
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
Poster Discussion – Gastrointestinal tumours, non-colorectal - Invited Discussant 677PD, 678PD, 679PD and 680PD
Presenter: Russell Petty
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
Poster Discussion – Gastrointestinal tumours, non-colorectal - Invited Discussant 681PD and LBA47
Presenter: Ana Raimundo
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
6574 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Presenter: Ahmed Kaseb
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4638 - Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Presenter: Eric Van Cutsem
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5708 - Chemotherapy for Frail and Elderly Patients (pts) with Advanced Gastroesophageal Cancer (aGOAC): Quality of Life (QoL) results from the GO2 Phase III Trial
Presenter: Peter Hall
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2878 - First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-_, in patients with advanced hepatocellular cancer (HCC)
Presenter: Debashis Sarker
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
1203 - Systemic gut microbial metabolites limit the anti-tumor effect of CTLA-4 blockade in hosts with cancer.
Presenter: Clelia Coutzac
Session: Proffered Paper session - Basic Science
Resources:
Abstract